{"id":38676,"date":"2026-06-04T11:13:00","date_gmt":"2026-06-04T15:13:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=38676"},"modified":"2026-05-03T20:46:04","modified_gmt":"2026-05-04T00:46:04","slug":"the-hidden-hiring-signal-what-patent-cliff-events-tell-you-about-workforce-shifts-in-big-pharma","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/the-hidden-hiring-signal-what-patent-cliff-events-tell-you-about-workforce-shifts-in-big-pharma\/","title":{"rendered":"The Hidden Hiring Signal: What Patent Cliff Events Tell You About Workforce Shifts in Big Pharma"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Before a pharmaceutical company files a single WARN notice, before a restructuring plan hits an SEC filing, before a CEO stands before analysts to announce a ‘cost optimization program,’ the signal is already visible. It sits in a USPTO database entry. It lives in an FDA Orange Book listing. Patent expiration dates, with their precise legal precision, function as one of the most reliable leading indicators of workforce disruption anywhere in corporate America.<\/p>\n\n\n\n

This is not speculation. It is a pattern that has repeated with enough consistency over three decades of pharmaceutical business cycles that industry veterans treat it like clockwork. A blockbuster drug moves within 36 months of its loss of exclusivity (LOE), and the organizational chart of the company that owns it starts contracting. Sales territories consolidate. Medical science liaisons assigned to that franchise get calls from HR. The legal and regulatory teams that built the patent thicket around the asset start fielding departure meetings. And somewhere across town, or across the country, a generics manufacturer or a biosimilar developer begins posting aggressively for the exact same roles.<\/p>\n\n\n\n

What makes the current cycle different from anything that came before is sheer scale. Between 2025 and 2030, more than $300 billion in prescription drug revenues will lose patent exclusivity, about one-sixth of the industry’s annual revenue. Nearly 200 drugs will see their patents expire in this window, including about 70 blockbusters generating over $1 billion each in annual sales. The previous patent cliff, centered around 2012, involved Lipitor, Plavix, and a handful of oral small molecules. The previous patent cliff, in 2016, eroded about $100 billion in brand-name sales. The current one is three times that size.<\/p>\n\n\n\n

If you are a pharmaceutical executive, a management consultant, a recruiter with a healthcare practice, or a professional currently embedded in the commercial or R&D organization of a major drug company, the patent calendar is your map. It tells you where the jobs are leaving, where they are being created, and \u2014 critically \u2014 how much lead time you have before the transition accelerates.<\/p>\n\n\n\n

This article maps the specific expiry events driving the current restructuring wave, traces the workforce consequences by role type and company, and identifies where the real hiring growth is concentrated. The data is not pretty, but it is actionable.<\/p>\n\n\n\n

The Mechanism: Why Patent Expiry Reliably Precedes Layoffs<\/strong><\/h2>\n\n\n\n

To understand why patent dates function as workforce predictors, you need to understand the revenue model they protect.<\/p>\n\n\n\n

A blockbuster drug is not just a commercial product. It is an entire organizational ecosystem. A drug generating $5 billion per year in U.S. revenue typically supports a dedicated sales force of several hundred to several thousand representatives, a medical affairs team, a market access and payer relations function, a regulatory group managing post-marketing commitments, and a legal team sustaining the intellectual property perimeter. The drug pays for itself several times over, and it funds large portions of the organization’s overhead.<\/p>\n\n\n\n

When that drug loses its patent protection and generic competitors enter the market, the revenue arithmetic shifts with speed that shocks executives who have never lived through it before. Sales of the branded drug can plummet by as much as 80% to 90% within the first 12-18 months of generic or biosimilar entry. Competitors can capture the majority of the market in a matter of months. The organizational infrastructure that was justified by $5 billion in annual revenue cannot be justified by $500 million. The math produces layoffs.<\/p>\n\n\n\n

But the layoffs rarely arrive at the moment of expiry. Companies begin the restructuring earlier, typically 18 to 36 months before the LOE event, because the writing on the wall is visible to everyone. Patent dates are public information. Paragraph IV challenge filings are public information. Settlement agreements filed with the SEC are public information. The pharmaceutical industry runs on information asymmetries in many domains, but patent timelines are not one of them.<\/p>\n\n\n\n

Tools like DrugPatentWatch exist precisely because aggregating, tracking, and interpreting this information has competitive value. Patent expiry data, when combined with knowledge of a company’s revenue concentration, pipeline depth, and cost structure, gives investors, consultants, and career professionals a window into organizational futures that most people miss because they are not looking.<\/p>\n\n\n\n

The pattern runs in two directions simultaneously. As originator companies shed roles tied to expiring assets, generic and biosimilar manufacturers build capacity to exploit the same opportunity. The workforce does not disappear; it migrates. Understanding that migration creates opportunities for every category of professional paying attention.<\/p>\n\n\n\n

The 2025-2030 Cliff in Detail: The Drugs Driving the Disruption<\/strong><\/h2>\n\n\n\n

The current cycle is not a single cliff. It is a series of drops, each concentrated in a different therapeutic area, each with its own workforce implications. The table below captures the key expiry events driving the most significant organizational responses.<\/p>\n\n\n\n

Drug<\/th>Company<\/th>Indication<\/th>2023 Revenue<\/th>LOE Date<\/th>Revenue at Risk<\/th><\/tr>
Keytruda (pembrolizumab)<\/td>Merck & Co.<\/td>Oncology (PD-1)<\/td>~$25B<\/td>2028<\/td>$29.5B+<\/td><\/tr>
Eliquis (apixaban)<\/td>BMS \/ Pfizer<\/td>Cardiovascular<\/td>~$12-13B<\/td>2026-2028<\/td>$13B+<\/td><\/tr>
Opdivo (nivolumab)<\/td>Bristol Myers Squibb<\/td>Oncology (PD-1)<\/td>~$9B<\/td>2028<\/td>$9B+<\/td><\/tr>
Januvia \/ Janumet<\/td>Merck & Co.<\/td>Diabetes (DPP-4)<\/td>~$2.25B<\/td>May 2026<\/td>~$2B<\/td><\/tr>
Xeljanz (tofacitinib)<\/td>Pfizer<\/td>Immunology (JAK)<\/td>~$1.6B<\/td>2025-2026<\/td>~$1.6B<\/td><\/tr>
Ibrance (palbociclib)<\/td>Pfizer<\/td>Oncology (CDK4\/6)<\/td>~$5B<\/td>March 2027<\/td>~$5B<\/td><\/tr>
Dupixent (dupilumab)<\/td>Sanofi \/ Regeneron<\/td>Immunology (IL-4\/13)<\/td>~$11B<\/td>Early 2030s<\/td>$13B+<\/td><\/tr>
Stelara (ustekinumab)<\/td>Johnson & Johnson<\/td>Immunology<\/td>~$10B<\/td>2025 (US)<\/td>$10B+<\/td><\/tr>
Trintellix (vortioxetine)<\/td>Takeda<\/td>Psychiatry<\/td>~$1.5B<\/td>Dec. 2026<\/td>~$1.5B<\/td><\/tr>
Prevnar (pneumococcal)<\/td>Pfizer<\/td>Vaccines<\/td>~$6B<\/td>2026<\/td>~$6B<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

The numbers aggregate quickly. By 2026, eight of the 13 largest pharmaceutical firms, representing 55% of global market value, could see 30% or more of their revenue jeopardized, with losses ranging from $6 billion to $38 billion per company.<\/p>\n\n\n\n

Each of those numbers corresponds to a real organizational footprint. When BMS faces a $38 billion growth gap, that gap represents not just financial exposure but the specific teams, roles, and headcount that were justified by revenues that will no longer exist.<\/p>\n\n\n\n

Why This Cliff Is Structurally Different<\/strong><\/h3>\n\n\n\n

What makes the 2025-2030 cliff structurally different from past cycles is the type of drugs involved. Previous patent cliffs \u2014 the 2012 cliff, for example, when drugs like Plavix and Lipitor went generic \u2014 were dominated by oral small-molecule medicines in primary care categories. Replacing those revenues required large sales forces but relatively straightforward drug development expertise. The current cliff is concentrated in oncology, immunology, and cardiometabolic disease. The drugs expiring are biologics and first-in-class agents that succeeded because of scientific breakthroughs. Replacing them demands scientific platforms, specialized commercial infrastructure, and regulatory expertise that most companies have spent years building and still haven’t fully mastered.<\/p>\n\n\n\n

This structural difference matters enormously for workforce implications. When Lipitor went generic in 2011, Pfizer shed tens of thousands of primary care sales representatives \u2014 a large, relatively homogeneous population of commercially trained professionals. The current cliff is eliminating specialists: oncology sales representatives who have spent years cultivating relationships with academic medical centers, medical science liaisons with PhDs who understand PD-1 biology deeply enough to discuss it with physicians at grand rounds, market access professionals who have built relationships with pharmacy and therapeutics committees at major health systems.<\/p>\n\n\n\n

These roles are harder to recreate quickly. When they are eliminated, they represent real capability loss, not just headcount reduction. And when the biosimilar or follow-on competitors who benefit from these expirations need to build their own teams to compete in these therapeutic spaces, the same specialized talent pool is in high demand simultaneously.<\/p>\n\n\n\n

Company by Company: Reading the Organizational Signals<\/strong><\/h2>\n\n\n\n

Merck & Co.: The Keytruda Countdown<\/strong><\/h3>\n\n\n\n

No single patent expiry in the current cycle generates more anxiety inside a pharmaceutical boardroom than Keytruda’s 2028 LOE. Keytruda, currently the best-selling drug in the world, is expected to lose patent protection in 2028. The company generated roughly $25 billion in Keytruda sales in 2023, and the drug represented the majority of Merck’s revenue growth engine for the previous decade.<\/p>\n\n\n\n

The workforce response at Merck has been explicit. The company plans to cut approximately 6,000 jobs globally as part of a restructuring initiative targeting $3 billion in annual cost savings by 2027. According to the company, the restructuring will mainly affect administrative, sales, and R&D roles.<\/p>\n\n\n\n

The sequencing matters. Merck announced the $3 billion savings target and the 6,000 job reduction in mid-2025, roughly three years before Keytruda’s expected loss of exclusivity. This is exactly the lead time the pattern predicts. Companies do not wait for the cliff to arrive. They build the financial cushion before it hits, which means the workforce disruption starts years before the patent technically expires.<\/p>\n\n\n\n

Merck’s situation has a layer of complexity beyond just Keytruda. Merck’s core compound patent for Januvia expired in 2023, but a related salt\/polymorph patent ran into 2027. Facing Paragraph IV challenges, Merck settled in 2020 so that generics could launch in mid-2026. With Januvia and Janumet generics arriving in May 2026, Merck loses another $2+ billion revenue stream almost simultaneously with its Keytruda restructuring program.<\/p>\n\n\n\n

Where is Merck actually hiring? The company has been explicit about its strategic pivot toward oncology, vaccines, and what it calls ‘next-generation’ cardiometabolic therapies. It paid $10 billion for Verona Pharma, a respiratory specialist, in 2025. Every one of those acquisitions requires new clinical, regulatory, and commercial teams to integrate and launch the assets. The hiring is concentrated in oncology clinical development, regulatory affairs for biologics, and market access roles for specialty therapeutics \u2014 not in the primary care and diabetes functions tied to the expiring portfolio.<\/p>\n\n\n\n

Bristol Myers Squibb: The Most Exposed Company in Big Pharma<\/strong><\/h3>\n\n\n\n

BMS has the clearest and most dramatic patent cliff exposure of any large-cap pharmaceutical company. Eliquis, together with the company’s immuno-oncology flagship drugs Opdivo, accounts for roughly half of BMS’s total earnings. As both drugs approach the end of their exclusivity, the company faces what analysts describe as the largest growth gap among its large-cap pharmaceutical peers, estimated at approximately $38 billion in future at-risk revenue.<\/p>\n\n\n\n

The organizational response has been correspondingly aggressive. Shortly after becoming Bristol Myers Squibb’s CEO, Chris Boerner, Ph.D., initiated a restructuring with plans to slash $1.5 billion in costs by the end of 2025, which was extended last year to add another $2 billion in cutbacks to be achieved by the end of 2027. The cuts have been geographically specific. BMS filed a WARN alert indicating plans to lay off 223 employees at its Lawrenceville, New Jersey, facility. The reductions are scheduled to take effect between May 22 and August 1, 2025.<\/p>\n\n\n\n

Lawrenceville, New Jersey is not a random location. It is BMS’s primary U.S. commercial and administrative hub. WARN filings at that address are not site-specific manufacturing reductions; they are cuts to the commercial infrastructure supporting the company’s flagship brands.<\/p>\n\n\n\n

What is BMS building instead? The company’s strategic investments have concentrated in the cell therapy and protein degrader spaces, areas that require entirely different technical and commercial expertise than a cardiovascular anticoagulant franchise like Eliquis. This means the jobs being eliminated at BMS’s commercial organization in New Jersey are not being replaced internally. They are being replaced structurally, by a smaller, more science-focused organization with different skill requirements. The professionals coming out of the Eliquis commercial team need to recognize that their destination is not within BMS; it is at generics companies launching apixaban equivalents, at specialty pharmacy organizations managing anticoagulation programs, or at competitors building new cardiovascular portfolios.<\/p>\n\n\n\n

Pfizer: The Multi-Front Restructuring<\/strong><\/h3>\n\n\n\n

Pfizer’s situation is complicated by the post-COVID dynamics that inflated its headcount and revenue in 2021 and 2022. But the patent cliff component is real and measurable. Pfizer’s Xeljanz (tofacitinib) attained $1.6 billion in sales in 2023. After multiple new indications, Xeljanz’s patent family faced imminent challenges. In August 2025, FDA approved the first generic tofacitinib. That generic approval \u2014 a single FDA decision \u2014 effectively ended the commercial rationale for the entire Xeljanz sales organization.<\/p>\n\n\n\n

Ibrance, Pfizer’s CDK4\/6 inhibitor for breast cancer, is the larger concern. Pfizer secured a U.S. patent term extension that pushes the key patent out to March 2027, which effectively sets the entry point for meaningful generic pressure in its largest market. Ibrance generated roughly $5 billion per year at its peak. When generic palbociclib enters the market in 2027, the specialized oncology sales infrastructure supporting that franchise will need to be repurposed or eliminated.<\/p>\n\n\n\n

Pfizer’s broader restructuring predates the Ibrance cliff. In October 2023, Pfizer began a multi-year drive to save around $4 billion by the end of 2024. In a regulatory filing in May, the company outlined plans to reduce costs by an additional $1.5 billion by the end of 2027. The consistency of the savings targets across multiple years tells you this is not a one-time event. Pfizer is systematically reducing the cost base that was built during the blockbuster era, and patent expirations are the structural justification.<\/p>\n\n\n\n

Prevnar, Pfizer’s pneumococcal vaccine franchise, adds another dimension. Vaccine commercial teams have different competencies from oncology teams; they work with government purchasers, managed care organizations, and pediatric practices rather than oncologists and academic medical centers. When Prevnar faces competitive pressure in 2026, the workforce implications are distinct from those at BMS or Merck.<\/p>\n\n\n\n

Takeda: A Template for the Pattern in Action<\/strong><\/h3>\n\n\n\n

Takeda’s response to the Trintellix patent expiry is one of the most transparent and instructive examples of how the patent cliff-to-workforce shift pattern actually unfolds in real time. Trintellix, the antidepressant vortioxetine, faces patent expiry in December 2026 in the United States.<\/p>\n\n\n\n

Takeda announced layoffs in January 2026 impacting 243 field-based commercial employees across 47 states and Washington, DC. A company spokesperson explained that the workforce reduction is part of a strategic shift tied to the upcoming US patent expiration for its antidepressant Trintellix in December this year. The cuts come as the Japanese drugmaker reorganizes its US neuroscience sales force to respond to expected generic competition and is simultaneously reallocating resources toward future product launches that could create roughly 400 new commercial field roles.<\/p>\n\n\n\n

Read that sentence carefully. Takeda eliminated 243 neuroscience field roles tied to Trintellix and simultaneously projected approximately 400 new commercial field roles tied to pipeline assets. The net job count may end up positive, but the 243 people laid off in January 2026 will not automatically fill the 400 roles being created for different products requiring different relationships and potentially different therapeutic area expertise.<\/p>\n\n\n\n

This is the hiring signal in its clearest form: patent expiry produces not just job destruction but job transformation. The positions being created require different knowledge, different call points, and often different geographic footprints than the positions being eliminated. Career professionals who recognize this dynamic can position themselves for the transition rather than be caught by it.<\/p>\n\n\n\n

Takeda, pressured by a generic assault on its attention-deficit\/hyperactivity disorder drug Vyvanse, entered a companywide restructuring in 2024. The Japanese pharma already counted around 1,800 fewer employees as of the end of March 2025 than it did the year before despite steady increases in prior years. Vyvanse was one of the first clear examples in the current cycle. The pattern there repeated almost exactly: patent expires, generics enter, sales force contracts, and resources shift toward next-generation assets.<\/p>\n\n\n\n

Novo Nordisk: The Inverse Case<\/strong><\/h3>\n\n\n\n

The Novo Nordisk story in 2025-2026 is the opposite of the Merck or BMS narrative, and that contrast is itself a hiring signal. Major workforce expansions at GLP-1 heavyweights Eli Lilly and Novo Nordisk, which together added more than 36,000 employees during the period when the rest of large pharma was contracting.<\/p>\n\n\n\n

GLP-1 drugs like Ozempic and Wegovy are in the growth phase of their patent lifecycle \u2014 exactly the period when companies hire aggressively to support commercial expansion. This is not coincidental. Ozempic’s core semaglutide patent ends in early 2026 in some jurisdictions, but follow-on patents and dosage patents keep its market monopoly through 2031. Until those protections erode, Novo Nordisk’s commercial teams are building, not contracting.<\/p>\n\n\n\n

The Novo Nordisk exception confirms the rule. Companies in the pre-LOE growth phase of major assets hire broadly and aggressively. Companies within 24 to 36 months of LOE on major assets restructure and contract. The patent date is the leading indicator for both dynamics.<\/p>\n\n\n\n

It is worth noting that even Novo Nordisk’s growth trajectory hit a wall. Novo Nordisk announced plans to cut roughly 9,000 jobs (11.5% of its workforce) as part of a major restructuring aimed at saving about $1.26 billion per year. This followed eight years of headcount doubling from approximately 43,000 in 2019 to approximately 77,000 in 2024, driven by Wegovy\/Ozempic demand. The company scaled too aggressively in anticipation of demand that, while enormous, did not materialize as fast as the hiring had implied. The lesson is that the patent lifecycle is a necessary but not sufficient condition for predicting workforce trajectories; demand forecasting errors can create their own restructuring events even in growing franchises.<\/p>\n\n\n\n

The Aggregate Picture: 22,000 Positions and Counting<\/strong><\/h2>\n\n\n\n
\n

‘Seventeen large pharmaceutical companies, each with at least $20 billion in 2025 revenue, collectively reduced their workforces by more than 22,000 employees last year. This head count contraction comes as the biopharma industry braces for a massive $300 billion patent cliff in prescription drug revenues between 2025 and 2030.’\u2014 Fierce Pharma, March 2026 [1]<\/p>\n<\/blockquote>\n\n\n\n

The 22,000 figure from 2025 alone understates the cumulative disruption. After shedding more than 14,000 jobs in all of 2024, the industry surpassed 13,000 layoffs by July 2025, a 31% year-over-year increase at the halfway mark. And the pace of restructuring continues to accelerate, not decelerate, because the patent expiry events are still arriving.<\/p>\n\n\n\n

The 2026 schedule brings Januvia and Janumet generics in May, Xeljanz full generic entry, Prevnar competitive pressure, and Trintellix expiry in December. The 2027 schedule adds Ibrance generic entry and Lynparza expiry. In 2028, Keytruda and Eliquis face their own LOE events, which will likely be accompanied by another round of restructuring announcements in 2026 and 2027 as companies begin building the financial cushion in advance.<\/p>\n\n\n\n

Despite recent divestitures and savings initiatives, the net head count reduction across these 17 companies over the 2021-25 period was about 12,000. This smaller net decline can be attributed to major workforce expansions at GLP-1 heavyweights. Stripping out the Lilly and Novo Nordisk hiring that offset cuts elsewhere, the actual job destruction in legacy pharmaceutical commercial and administrative functions is substantially larger than the net number suggests.<\/p>\n\n\n\n

Bayer is a particular case study in large-scale restructuring with a clear patent cliff component. Under another new CEO initiative, Bayer began a reorganization in 2024 as Bill Anderson streamlined the German conglomerate’s structures. By the end of 2025, Bayer had about 88,000 employees, versus around 100,000 before the reorg. That 12,000-position reduction in two years represents an almost 12% workforce reduction at one of the world’s largest pharmaceutical companies \u2014 and it happened before several of Bayer’s key patent cliff events fully materialized.<\/p>\n\n\n\n

Role-Level Analysis: Who Gets Cut and When<\/strong><\/h2>\n\n\n\n

Understanding the workforce shift requires getting below the company level to specific role categories. Patent cliff events do not produce uniform workforce reduction. They produce structured reduction that follows predictable sequencing, and recognizing that sequence is how professionals and organizations can adapt before the transition reaches them.<\/p>\n\n\n\n

The First Wave: Sales Force Rationalization<\/strong><\/h3>\n\n\n\n

Sales organizations are the most visible casualty of patent expiry events. This is because their cost is high, their justification is direct \u2014 generating prescriptions for branded drugs \u2014 and their economic rationale evaporates immediately once generic substitution begins.<\/p>\n\n\n\n

For a primary care drug losing exclusivity, the dynamic is simple. Once generic versions are available, pharmacies substitute automatically in most U.S. states, physicians no longer need to be educated about prescribing the brand, and patient assistance programs shift to generic access programs. The sales representative who previously generated value by keeping Januvia top-of-mind for a primary care physician becomes irrelevant the month the generic launches.<\/p>\n\n\n\n

For specialty drugs in oncology or immunology, the timeline is less abrupt but the direction is the same. Biosimilar entry for a drug like Opdivo or Keytruda does not produce overnight substitution the way generic entry does for a small molecule, because biosimilars require physician education, payer contracting, and hospital formulary negotiation. But the commercial team’s value proposition erodes progressively, and companies typically begin sales force reductions 12 to 18 months before biosimilar entry rather than 6 months before.<\/p>\n\n\n\n

Merck’s restructuring of its diabetes commercial organization is illustrative. With generic sitagliptin arriving in May 2026, the sales representatives who covered endocrinologists and primary care physicians for Januvia have no productive commercial activity once generic substitution begins. Merck’s broader restructuring covers 6,000 positions, and the diabetes commercial team is among the earliest functions to rationalize.<\/p>\n\n\n\n

The Second Wave: Medical Affairs Contraction<\/strong><\/h3>\n\n\n\n

Medical science liaisons (MSLs) and the broader medical affairs function contract more slowly than sales, because they serve different purposes. Where sales representatives promote to prescribers, MSLs educate specialists on clinical data, manage relationships with key opinion leaders (KOLs), and support investigator-sponsored studies. Their work has a longer tail post-LOE because the clinical literature and KOL relationships they built continue to have value even after the commercial incentive is gone.<\/p>\n\n\n\n

But they do contract. When a drug like Eliquis faces biosimilar competition, the medical affairs function supporting it progressively loses its reason for existence. BMS and Pfizer do not need a team of PhDs explaining apixaban’s clinical data to cardiologists when generic apixaban is available for 80% less. The MSLs assigned to Eliquis are redeployed or eliminated within 18 to 36 months of biosimilar entry.<\/p>\n\n\n\n

The career opportunity here is significant. MSLs in therapeutic areas affected by patent cliffs find themselves in demand at three different types of organizations: the biosimilar manufacturers who need KOL relationships and clinical education capabilities in those same therapy areas; the medical communication companies that support both originator transition and biosimilar commercial launches; and the academic medical centers and professional societies that increasingly receive these professionals into fellowship and faculty roles.<\/p>\n\n\n\n

The Third Wave: Regulatory and Legal Affairs<\/strong><\/h3>\n\n\n\n

Patent cliff events create a specific kind of regulatory and legal activity that generates a temporary hiring surge even as the broader organization contracts. When a drug approaches LOE, the originator’s regulatory team works to pursue new formulations, new indications, and new dosing presentations that might extend the product’s commercial life. This lifecycle management work is intensive and requires specialized expertise in the relevant therapy area.<\/p>\n\n\n\n

Simultaneously, the legal team managing the intellectual property becomes acutely important. Patent challenges \u2014 Paragraph IV certifications under the Hatch-Waxman Act \u2014 are filed by generics manufacturers years before the actual LOE event, and each challenge requires legal resources to litigate or negotiate. AbbVie built more than 130 patents around Humira over two decades, creating a patent thicket that delayed U.S. biosimilar entry until 2023 despite the core patent expiring years earlier. The teams that build those thickets and then defend them in litigation are highly specialized and well compensated.<\/p>\n\n\n\n

After the LOE event occurs and all the lifecycle management work is complete, however, the regulatory and legal functions tied to the aging asset contract. The settlements are signed, the lifecycle management filings are submitted, and the asset enters a maintenance mode that requires far fewer specialized resources.<\/p>\n\n\n\n

The Fourth Wave: Manufacturing and Supply Chain Rationalization<\/strong><\/h3>\n\n\n\n

Manufacturing is the slowest wave but often the largest in absolute job terms. Pharmaceutical manufacturing facilities are capital-intensive, geographically fixed, and represent multi-billion-dollar infrastructure investments. They do not close quickly.<\/p>\n\n\n\n

But they do close. Merck announced it is closing its manufacturing facility in Pennsylvania and will lay off 163 employees in the process. Pfizer similarly rationalized manufacturing across multiple U.S. sites as its post-COVID revenue normalization intersected with patent cliff pressures on its older portfolio.<\/p>\n\n\n\n

For manufacturing professionals, the patent cliff creates a clear geographic hiring signal. As originator manufacturing facilities in established locations reduce production or close entirely, the generic and biosimilar manufacturers who will supply the market are building capacity. Many of those manufacturers are located in different geographies \u2014 Indian generics companies, Chinese biosimilar manufacturers, and European specialty pharma firms often do not have the U.S. manufacturing footprint that the originator does. But the CDMOs (contract development and manufacturing organizations) serving those companies are frequently U.S.-based and are hiring production scientists, quality assurance professionals, and regulatory manufacturing specialists as they scale to meet demand.<\/p>\n\n\n\n

How to Read Patent Data as a Hiring Signal: A Practical Framework<\/strong><\/h2>\n\n\n\n

The gap between having access to patent expiry data and actually using it as a predictive tool for workforce shifts is a methodology gap, not an information gap. The data is publicly available. The tools to aggregate it exist. The challenge is building the analytical framework that connects patent events to organizational consequences with enough specificity to be actionable.<\/p>\n\n\n\n

Step One: Map Revenue Concentration<\/strong><\/h3>\n\n\n\n

The first question to answer about any company is: what share of revenue is concentrated in assets facing LOE in the next 36 months? A company with 30% of revenue at risk from a single drug makes very different organizational decisions than a company with 30% of revenue spread across ten drugs in various stages of their patent life.<\/p>\n\n\n\n

BMS is the extreme example of dangerous concentration. BMS faces the steepest proportional cliff with 47% of revenues at risk by 2030. Eliquis ($13B) and Opdivo ($9B) together represent about 45% of total revenues. That level of concentration in two assets, both approaching LOE in the same window, is the organizational equivalent of a building with two load-bearing walls both showing cracks. The response has to be aggressive restructuring combined with rapid pipeline development, and both of those things have workforce consequences.<\/p>\n\n\n\n

J&J provides an instructive contrast. When Stelara began facing biosimilar competition, J&J’s overall top-line revenue grew by 5.8% in the same period despite Stelara’s Q2 sales dropping by 42.7% year-over-year. This result reveals a critical distinction in corporate philosophy. J&J’s strategy is one of deep diversification. Companies with diversified portfolios absorb LOE events without the existential restructuring that concentrated companies undergo.<\/p>\n\n\n\n

Step Two: Identify the Timing Window<\/strong><\/h3>\n\n\n\n

Patent expiry dates are specific, but the organizational response to them follows a predictable timing pattern that varies by asset type and company financial condition.<\/p>\n\n\n\n

For small-molecule drugs, the organizational response typically begins 24 to 36 months before LOE, accelerates in the 12 months prior, and completes its first phase within 6 to 12 months of generic entry. The timeline is shorter because generic substitution is fast and automatic.<\/p>\n\n\n\n

For biologics, the organizational response begins 36 to 48 months before LOE because biosimilar market entry is more complex and pricing erosion is slower. Companies have more time to plan, but they use that time to begin restructuring earlier rather than delay it.<\/p>\n\n\n\n

Mapping these timing windows against known LOE dates produces a calendar of organizational events that has real predictive value. Knowing that Keytruda faces LOE in 2028, and that biologic restructuring begins 36 to 48 months prior, means the Merck restructuring calendar runs from approximately 2024 through 2028. Merck’s announcement of the $3 billion savings plan in mid-2025 sits exactly in that window.<\/p>\n\n\n\n

Step Three: Use Patent Intelligence Tools<\/strong><\/h3>\n\n\n\n

Translating patent data into actionable workforce intelligence requires data infrastructure. DrugPatentWatch is the most widely used platform for tracking patent expiry dates, Paragraph IV challenges, Orange Book listings, and LOE timelines across the entire FDA-regulated pharmaceutical market. Its utility extends beyond investment research to competitive intelligence, business development, and \u2014 for the purposes of this analysis \u2014 workforce planning.<\/p>\n\n\n\n

A recruiter with a pharmaceutical practice who uses DrugPatentWatch to identify which drugs face LOE in the next 24 months has a sourcing map. The commercial organizations tied to those drugs are the most predictable sources of available talent. The biosimilar and generics manufacturers who will compete in those therapeutic areas are the most predictable destinations for that talent.<\/p>\n\n\n\n

Patent data is also useful for identifying where companies are building new IP positions \u2014 the drugs around which they are filing new patents, pursuing new indications, and assembling regulatory packages. Those IP investments indicate where hiring is going to concentrate. A company filing aggressively in antibody-drug conjugates (ADCs) is building toward commercial launches in oncology that will require specialized MSLs, market access professionals, and clinical development scientists with ADC expertise.<\/p>\n\n\n\n

Step Four: Cross-Reference with Public Filings<\/strong><\/h3>\n\n\n\n

SEC filings are the ground truth for workforce changes. Companies in the United States are required to file WARN Act notices for layoffs of 50 or more employees at a single location, and while these filings are state-level and somewhat fragmented, they provide precise geographic and timing information for specific workforce reductions. Major restructuring programs are also disclosed in 10-K and 10-Q filings, with company-level headcount data that tracks organizational size over time.<\/p>\n\n\n\n

The combination of patent expiry data from DrugPatentWatch with SEC filing analysis creates a two-layer signal. The patent data tells you which organizational functions will be under pressure and when. The SEC filings tell you which restructuring programs are already active and at what stage they are. Together, they give a 12-to-36-month look-ahead on workforce shifts that no single data source provides alone.<\/p>\n\n\n\n

Where the Jobs Are Actually Growing<\/strong><\/h2>\n\n\n\n

The narrative of patent cliff workforce disruption focuses, understandably, on job loss. But the same patent cliff that is eliminating roles at Merck and BMS is simultaneously creating roles at other organizations in the same ecosystem. The opportunity is not symmetric \u2014 some professional categories face far more disruption than they face opportunity \u2014 but it is real.<\/p>\n\n\n\n

Generics and Biosimilar Manufacturers<\/strong><\/h3>\n\n\n\n

The most direct beneficiary of the current patent cliff is the generics and biosimilar manufacturing sector. The patent cliff creates a clear transfer of value to generic and biosimilar manufacturers, whose business model is bifurcating into a high-volume, low-margin segment for simple drugs and a high-complexity, high-value segment for biologics.<\/p>\n\n\n\n

Companies like Teva, Viatris, Sandoz, and a range of Indian generics manufacturers \u2014 Dr. Reddy’s, Cipla, Sun Pharma \u2014 are active in building U.S. commercial capacity for the wave of generic launches between 2026 and 2030. Each generic launch requires regulatory affairs professionals to manage ANDA submissions, quality assurance scientists to maintain FDA compliance, market access specialists to negotiate with pharmacy benefit managers and retail pharmacy chains, and commercial teams to compete for formulary placement.<\/p>\n\n\n\n

The biosimilar space requires a more sophisticated commercial infrastructure. Biosimilar launches in oncology and immunology require the same type of specialized clinical and medical affairs expertise that the originator built over years. In November 2025, Formycon announced progress with FYB208, a dupilumab biosimilar candidate, including completed preclinical development and preparation for clinical studies. For every biosimilar candidate in development, there is a commercial team, a medical affairs function, and a market access organization being built in anticipation of the LOE event.<\/p>\n\n\n\n

M&A Integration Specialists<\/strong><\/h3>\n\n\n\n

The patent cliff is driving pharmaceutical M&A at historic rates. Total pharma M&A deal value reached $240 billion in 2025, an 81% year-over-year increase, making it the strongest M&A year since 2019. ING projects 15% growth in both deal value and number of deals in 2026, forecasting nearly 520 deals totaling over $230 billion.<\/p>\n\n\n\n

Every acquisition requires integration work. Business development professionals who can identify and execute acquisitions of pipeline assets, regulatory specialists who can lead due diligence on the IP position of acquisition targets, and program management professionals who can manage integration while preserving the scientific value of the acquired asset are in sustained high demand across the industry.<\/p>\n\n\n\n

Sun Pharma’s acquisition of Organon for $11.75 billion in April 2026 is one recent example. That deal brings 70 products across women’s health and biosimilars into Sun Pharma’s portfolio. Integrating that product breadth requires teams at both companies who understand regulatory, commercial, and scientific aspects of each asset. The integration hiring for a deal that size runs into the hundreds of positions over a 12-to-24-month period.<\/p>\n\n\n\n

Clinical Development in Priority Therapeutic Areas<\/strong><\/h3>\n\n\n\n

Companies replacing expiring blockbusters with next-generation pipeline assets are investing heavily in clinical development. Merck’s pivot toward oncology succession assets, BMS’s investment in protein degraders and cell therapies, and Pfizer’s continued ADC development all require clinical operations infrastructure: clinical project managers, data managers, biostatisticians, regulatory medical writing specialists, and clinical research associates who manage site relationships.<\/p>\n\n\n\n

The therapeutic areas receiving this investment \u2014 oncology, immunology, neuroscience, and cardiometabolic disease \u2014 require specialists, not generalists. A clinical project manager who spent ten years running primary care trials in diabetes has a different and less immediately portable skill set than one who has managed oncology trials at academic medical centers. Companies recognize this and are paying premium compensation for specialists with relevant therapeutic area depth.<\/p>\n\n\n\n

Digital, AI, and Manufacturing Technology Roles<\/strong><\/h3>\n\n\n\n

Most layoffs in 2025 are tied to strategic realignment. ‘Companies are doubling down on core therapeutic areas and high-potential pipelines while cutting programs that fall outside their long-term focus.’ Part of that realignment is investment in automation, AI-enabled drug discovery, and digital health infrastructure. Pfizer’s restructuring has explicitly referenced increasing automation and digital enablement as part of its headcount reduction rationale \u2014 the positions being eliminated are not always being replaced by humans doing the same work.<\/p>\n\n\n\n

The hiring that is growing in this domain is in roles that sit at the intersection of pharmaceutical expertise and data science: AI-enabled clinical trial design, digital biomarkers for patient selection, automated manufacturing process control, and regulatory technology for electronic submission management. These roles require background that the professionals displaced by patent cliff restructuring do not always have, which is part of why the career transition from legacy commercial or regulatory roles into this domain is non-trivial.<\/p>\n\n\n\n

The reshoring trend adds another dimension to manufacturing hiring specifically. ‘The shift to bring more manufacturing back to the U.S.’ has become a driver of domestic pharmaceutical manufacturing investment. This creates hiring demand for pharmaceutical manufacturing engineers, quality systems professionals, and regulatory manufacturing specialists at domestic CDMO facilities that are scaling to serve the demand previously met by offshore production.<\/p>\n\n\n\n

Geographic Dimensions: Where the Workforce Shifts Are Concentrated<\/strong><\/h2>\n\n\n\n

Patent cliff workforce disruption is not uniformly distributed across geographies. It concentrates in specific pharmaceutical hubs where originator companies have their major commercial and administrative presences, and the replacement hiring concentrates in different locations where generics, biosimilar, and biotech companies are based.<\/p>\n\n\n\n

New Jersey’s pharmaceutical corridor \u2014 running through Lawrenceville (BMS), Kenilworth (Merck), and Pearl River (Pfizer) \u2014 is ground zero for the current restructuring wave. BMS’s WARN filings at Lawrenceville, Merck’s Cherokee facility closure in Pennsylvania, and Pfizer’s ongoing rationalization across multiple sites all cluster in this region. Professionals in this corridor who are in commercial, regulatory, and administrative roles tied to expiring assets face the most direct and immediate career disruption.<\/p>\n\n\n\n

The San Francisco Bay Area faces its own version of the disruption, concentrated in biotech. The Seagen acquisition by Pfizer, and the subsequent rationalization of the Seagen headquarters in Bothell, Washington, is a geographic-specific example. Pfizer plans to lay off at least 100 employees at its recently acquired Seagen HQ. Bothell, Washington is not a major pharmaceutical hub. The professionals displaced there face a thinner local market than their New Jersey counterparts.<\/p>\n\n\n\n

The growth hiring is concentrated in a different geography. Cambridge, Massachusetts and the surrounding Greater Boston area has become the primary destination for pharmaceutical R&D hiring, as companies invest in new molecular entities, biologics platforms, and clinical development capabilities. San Diego is a secondary hub. The Midwest, particularly Chicago and Indianapolis (Eli Lilly’s home), represents a mid-tier growth geography.<\/p>\n\n\n\n

Internationally, the geography of workforce shifts reflects manufacturing sourcing patterns. Indian generic manufacturers building U.S. commercial capacity are hiring in New Jersey and the Mid-Atlantic states. European biosimilar companies expanding into the U.S. market are hiring in both their home markets and in the U.S. commercial hubs. Chinese pharmaceutical companies that have signed major licensing deals with U.S. and European originators are building regulatory and business development capabilities in both geographies.<\/p>\n\n\n\n

The IRA Overlay: A Second Cliff Running Alongside the Patent Cliff<\/strong><\/h2>\n\n\n\n

The patent cliff analysis would be incomplete without acknowledging the Inflation Reduction Act, which creates a parallel pressure on pharmaceutical revenues that interacts with but is distinct from patent expiry.<\/p>\n\n\n\n

The Inflation Reduction Act (IRA) of 2022 introduced the first direct Medicare price negotiation authority in U.S. history, targeting a small set of drugs each year beginning in 2026. For drugs already facing LOE, the negotiated prices are largely irrelevant \u2014 generic and biosimilar competition will reduce prices far more aggressively than any HTA negotiation. The IRA’s effect is primarily on drugs with remaining exclusivity periods, particularly biologics.<\/p>\n\n\n\n

For drugs like Eliquis, the IRA and the patent cliff are running simultaneously. Eliquis, which generated $13.3 billion in combined sales for the two companies, is among the first drugs subject to Medicare price negotiations and will see its list price drop to $231 per month in 2026. U.S. patent protection for the drug is set to expire in 2028. The negotiated price reduction arrives before the generic competition, effectively compressing revenue in two separate ways before the LOE event itself.<\/p>\n\n\n\n

For workforce purposes, the IRA’s primary organizational consequence is in market access functions. The payer relations teams, government affairs professionals, and health economics and outcomes research (HEOR) specialists who manage relationships with CMS and Medicare are in higher demand than they were before the IRA, because the negotiation process requires dedicated expertise. At the same time, the traditional market access work of negotiating formulary placement and rebate structures with PBMs is affected by IRA-driven pricing dynamics in ways that require updated capabilities.<\/p>\n\n\n\n

Companies with drugs in the IRA negotiation pipeline need HEOR professionals who can build value dossiers that withstand CMS scrutiny. This is a specialized capability that differs from the commercial market access work that was standard before 2022. The workforce demand for IRA-competent HEOR and government affairs professionals has grown sharply since the first negotiated prices were announced, and this demand continues regardless of how specific patent cliff events unfold.<\/p>\n\n\n\n

The Biosimilar Complexity: Not Your Father’s Generic Competition<\/strong><\/h2>\n\n\n\n

The increasing share of biologics in the expiring portfolio fundamentally changes the nature of the competitive response and therefore the nature of the workforce shift. Generic small-molecule drugs are, in principle, chemically identical to the originator. Approval is straightforward. Market entry is fast. Commercial teams are lean. The workforce implications for originator companies are severe and rapid.<\/p>\n\n\n\n

Biosimilars are structurally more complex. They are highly similar but not chemically identical to their reference biologic. Their approval requires clinical data demonstrating comparable efficacy and safety. Their commercial uptake depends on physician education, payer contracting, and hospital formulary decisions in ways that generic substitution does not. Unlike the 2008 cliff, this period features a higher share of biologics, which face slower but substantial erosion from biosimilars, driven by faster regulatory approvals from the FDA and the European Medicines Agency.<\/p>\n\n\n\n

The Humira precedent is instructive here. AbbVie built more than 130 patents around adalimumab, creating a patent thicket that delayed U.S. biosimilar entry to 2023 despite the core compound patent expiring years earlier. Since the U.S. launch of Humira biosimilars in 2023, discounts have ranged from 5% to 85% off the drug’s list price. Despite this, adoption has been gradual, largely due to AbbVie’s aggressive contracting and rebate strategies with pharmacy benefit managers, which have helped it retain approximately 77% market share as of Q2.<\/p>\n\n\n\n

This means biosimilar-facing originator companies face a slower workforce transition than small-molecule generic-facing ones. They have more time to redeploy talent, more time to execute lifecycle management strategies, and more time to build out the replacement pipeline. But the fundamental direction of the organizational transition is the same: downward for teams supporting the aging biologic, upward for teams supporting successor assets.<\/p>\n\n\n\n

For biosimilar manufacturers themselves, the commercial complexity of biologic markets means their commercial organization requirements are far more sophisticated than generics companies’ were in the 2012 cycle. A company launching a Keytruda biosimilar in 2029 needs a specialized oncology commercial team, a medical affairs organization capable of engaging academic medical center pharmacy and therapeutics committees, and a market access function sophisticated enough to navigate group purchasing organization contracting in the hospital channel. The hiring required to build that infrastructure is significant and requires specialists \u2014 not the relatively interchangeable sales representatives who dominated the 2012 generics wave.<\/p>\n\n\n\n

Career Strategy for Pharmaceutical Professionals<\/strong><\/h2>\n\n\n\n

The patent cliff is not an abstract industry dynamic. For the hundreds of thousands of professionals working in pharmaceutical commercial, R&D, regulatory, and manufacturing functions, it is a live career risk. Understanding how to read it, and how to position relative to it, is practical and actionable.<\/p>\n\n\n\n

Identify Your Asset Exposure<\/strong><\/h3>\n\n\n\n

The first step is straightforward: know where in the patent lifecycle the drug or franchise you support sits. If your primary responsibility is a product with less than 36 months of U.S. patent exclusivity remaining, you are working in a contracting organizational unit. That is not necessarily a crisis, but it is a fact that should inform your career planning.<\/p>\n\n\n\n

DrugPatentWatch provides the Orange Book data, patent term information, and Paragraph IV challenge status for essentially every FDA-approved drug. Checking the patent status of your primary product takes fifteen minutes and provides clarity that most pharmaceutical professionals do not have because they have never specifically looked for it.<\/p>\n\n\n\n

Build Transferable Therapeutic Area Depth, Not Product Depth<\/strong><\/h3>\n\n\n\n

The most common career transition mistake in the pharmaceutical industry is confusing product knowledge with therapeutic area expertise. A medical science liaison who knows Keytruda’s clinical data deeply is an expert on pembrolizumab. But one who also understands PD-1 biology broadly, knows the competitive oncology landscape, has relationships with key opinion leaders in solid tumor oncology, and understands the clinical design of combination immunotherapy trials has durable expertise that transfers to any follow-on asset in the same space.<\/p>\n\n\n\n

When restructuring hits a franchise, the professionals who survive within the reorganized company or land quickly at a new organization are those with durable therapeutic area expertise, not those with deep single-product knowledge. Build toward the therapeutic area; the specific product credentials are table stakes.<\/p>\n\n\n\n

Understand the Biosimilar and Generics Employer Landscape<\/strong><\/h3>\n\n\n\n

The companies hiring most aggressively in the wake of patent cliff events are often less visible than the large originators doing the restructuring. Sandoz, newly independent from Novartis, is building its U.S. biosimilar commercial infrastructure. Viatris, created from the combination of Pfizer’s off-patent drug business with Mylan, is a major employer in legacy pharmaceutical roles. The Indian generics companies with U.S. commercial ambitions \u2014 Sun Pharma, Dr. Reddy’s, Cipla \u2014 are actively building U.S. commercial and regulatory teams.<\/p>\n\n\n\n

These employers differ from Big Pharma originators in culture, compensation structure, and career trajectory. They typically pay less in base salary but have different performance-upside structures, and they offer the specific career experience of working in a competitive generics or biosimilar launch environment that is genuinely different from originator experience. Professionals who cross that boundary early in the restructuring cycle \u2014 before the competition for those roles intensifies as more people exit originator companies \u2014 are in the best position.<\/p>\n\n\n\n

Consider the CRO and CDMO Ecosystem<\/strong><\/h3>\n\n\n\n

Contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) absorb a meaningful fraction of the talent displaced by pharmaceutical restructuring. These organizations provide R&D and manufacturing services to pharmaceutical companies of all sizes, and their business grows when pharma companies outsource functions that were previously done in-house as a cost reduction measure.<\/p>\n\n\n\n

When Merck cuts 6,000 positions, some portion of the work those 6,000 people were doing does not disappear. It gets outsourced to ICON, Parexel, Covance, or one of the other major CROs. Those CROs then hire to absorb the additional work. The compensation is typically somewhat lower and the work culture is different \u2014 CRO professionals manage multiple clients and projects simultaneously rather than embedding deeply in a single therapeutic area \u2014 but the career transition can be managed.<\/p>\n\n\n\n

For Recruiters and Talent Acquisition Professionals<\/strong><\/h2>\n\n\n\n

If you work in pharmaceutical talent acquisition, or if you are a recruiter with a pharmaceutical client base, the patent cliff provides you with a sourcing calendar that most of your competitors are not using systematically. The workflow is straightforward.<\/p>\n\n\n\n

Identify the drugs with LOE events in the next 12 to 36 months. Map those drugs to their primary commercial and regulatory organizations. Those organizations represent predictable sources of available, qualified talent in specific therapeutic areas. The professionals working in those functions are not necessarily looking for a new role today, but they are statistically likely to be looking within the next 12 to 24 months as restructuring waves hit their organizations.<\/p>\n\n\n\n

Proactive outreach to pharmaceutical professionals working in Merck’s diabetes commercial organization, BMS’s cardiovascular franchise, or Pfizer’s immunology business unit today is more productive than reactive sourcing after their WARN filings arrive. By then, every competitor in the market is reaching the same candidate pool simultaneously.<\/p>\n\n\n\n

On the hiring side, the biosimilar manufacturers, specialty generics companies, and pipeline-stage biotechs that need the talent these professionals represent are not always visible to professionals whose entire career has been at large originator companies. Making those connections \u2014 between the commercial talent exiting BMS’s Eliquis organization and the biosimilar manufacturer building an anticoagulant team \u2014 is exactly the value a pharmaceutical-specialized recruiter with patent intelligence can provide.<\/p>\n\n\n\n

For Business Consultants and Strategy Professionals<\/strong><\/h2>\n\n\n\n

Management consulting and pharmaceutical strategy consulting are significant professional consumers of patent cliff analysis. The specific application of patent timeline data to organizational design is less developed as a practice than it should be, and this gap represents a service opportunity.<\/p>\n\n\n\n

Companies undergoing restructuring in response to patent cliff events face a specific organizational design challenge: they need to right-size the commercial and administrative infrastructure supporting expiring assets while simultaneously building the capability needed to launch successor products. These two actions pull in opposite directions, and they require different timing. Contracting happens before the LOE event; building happens before the successor product launch. Synchronizing those two timelines while maintaining organizational capability and morale is a genuine management challenge that benefits from rigorous analytical support.<\/p>\n\n\n\n

Patent expiry data, combined with pipeline analytics and commercial capability assessment, provides the analytical foundation for that organizational design work. Consultants who can operationalize that combination \u2014 moving from DrugPatentWatch LOE data to workforce planning recommendations with specific role-level granularity \u2014 are providing a service that is both differentiated and directly tied to client value.<\/p>\n\n\n\n

The consulting engagement model around patent cliff organizational design typically runs in three phases. The first phase is analytical: mapping the company’s revenue concentration against the patent calendar, identifying which assets face LOE in which timeframes, and sizing the organizational footprint tied to each asset. This phase uses patent intelligence tools, annual report headcount data, and competitive benchmarking to produce a baseline view of exposure.<\/p>\n\n\n\n

The second phase is strategic: identifying which successor assets the company is backing, what commercial and scientific capabilities those assets require, and what the gaps are between the current organization and the capability model needed to succeed with successor assets. This phase draws on pipeline data, clinical development stage information, and therapeutic area commercial benchmarks to define the target organizational state.<\/p>\n\n\n\n

The third phase is transition planning: defining the sequence of organizational changes needed to move from the current state to the target state, including the specific role types to eliminate, the specific roles to create, the timing of each action relative to LOE events and pipeline milestone dates, and the workforce transition support needed to manage the human element of those changes responsibly. This is where the consulting engagement produces specific deliverables with direct organizational consequence \u2014 and where the quality of the underlying patent intelligence makes the difference between a high-confidence recommendation and an analytically thin restructuring plan.<\/p>\n\n\n\n

Strategy consultants who understand how to read patent expiry data as an organizational signal can offer a level of specificity to pharmaceutical clients that generalist restructuring advice cannot match. The same applies to executive search firms, investment banks with pharmaceutical advisory practices, and human capital advisory firms. Patent data is public and accessible, but converting it into organizational insight requires both the analytical framework and the pharmaceutical domain knowledge to apply it correctly.<\/p>\n\n\n\n

The Talent Supply and Demand Imbalance: What Actually Happens When Big Pharma Cuts<\/strong><\/h2>\n\n\n\n

The textbook assumption when a large company announces a restructuring is that the displaced talent flows efficiently into the job market and is absorbed by alternative employers. In pharmaceutical patent cliff restructurings, the reality is more complicated, and the complications vary systematically by role type, therapeutic area, and geographic location.<\/p>\n\n\n\n

Supply Surges That Outpace Demand<\/strong><\/h3>\n\n\n\n

When BMS eliminates 2,200 positions from its New Jersey facilities, it is releasing a large cohort of pharmaceutical professionals into the same regional market at approximately the same time. The competitive dynamics for that talent pool are unfavorable: many people with similar backgrounds in cardiovascular commercial work are available simultaneously, which compresses compensation expectations and extends job search timelines.<\/p>\n\n\n\n

This surplus condition in specific role categories is predictable from the patent data. Any major LOE event affecting a drug with a large, homogeneous commercial team \u2014 dozens of primary care representatives in similar geographies with similar territory structures \u2014 produces a local surplus of that specific talent. The generics manufacturers who will launch competing products hire smaller commercial teams because the economics of generic products do not support large branded sales forces. The net result is that more people are available than the market for those roles can absorb at anything approaching their previous compensation levels.<\/p>\n\n\n\n

The surplus is not uniform across all role types. Specialized clinical and regulatory roles face a different dynamic because the supply of genuinely experienced biologics regulatory specialists, PD-1 oncology medical science liaisons, and market access professionals with IRA negotiation experience is structurally limited. These people are not created quickly, and the pipeline of replacements entering the pharmaceutical workforce from graduate and post-graduate programs at any given time is relatively small. When multiple companies restructure simultaneously and those specialized roles are affected, the surplus is modest relative to the alternative-employer demand. Those professionals land faster and at comparable or better compensation.<\/p>\n\n\n\n

The ‘Last Man Standing’ Dynamic in Contracting Franchises<\/strong><\/h3>\n\n\n\n

One pattern that experienced pharmaceutical restructuring professionals recognize, and that the patent cliff intensifies, is what might be called the last-man-standing dynamic. When a franchise enters restructuring mode with multiple rounds of cuts, the professionals who survive early rounds often face deteriorating conditions: a smaller team doing the same work, reduced resources for programs they manage, and ongoing uncertainty about whether the next restructuring round will reach their function.<\/p>\n\n\n\n

For professionals in that position, the rational career decision is often to leave before being pushed out \u2014 to use the organizational uncertainty as a catalyst for an intentional career move rather than waiting passively for the restructuring to progress to their tier. Those who move proactively, 12 to 24 months before the LOE event fully materializes, enter the job market when the supply is thinner and employer demand for their skills is higher. Those who wait until the formal layoff arrive during a competitive moment.<\/p>\n\n\n\n

This is one of the more counterintuitive aspects of patent cliff career planning: the professionals who use patent expiry data to act earlier than the layoff cycle reaches them systematically outperform those who wait. The irony is that the same data that should prompt action is publicly available and commonly known in the industry; the gap is not informational but psychological and behavioral. Most people prefer certainty of current employment to the uncertainty of an early voluntary transition, even when the expected value of the early transition is higher.<\/p>\n\n\n\n

Geographic Arbitrage in Pharmaceutical Talent Markets<\/strong><\/h3>\n\n\n\n

The geographic concentration of patent cliff restructuring in specific pharmaceutical hubs creates an arbitrage opportunity for professionals willing to relocate. The New Jersey corridor is simultaneously the largest source of displaced pharmaceutical talent and the most competitive local market for alternative pharmaceutical employment, because most of the originator companies that could offer comparable employment are located in the same region and undergoing their own restructuring.<\/p>\n\n\n\n

Relocating to Greater Boston, San Diego, or the Research Triangle Park in North Carolina \u2014 where biotech hiring is more active and the supply of displaced originator talent is thinner \u2014 produces better outcomes for most pharmaceutical professionals displaced by patent cliff restructuring. The challenge is that relocation willingness correlates inversely with seniority: the most senior and therefore most valuable professionals are the most rooted in established locations, which creates a structural tension in the market. Younger professionals willing to relocate access the best opportunities; senior professionals often accept worse terms or longer search durations by staying local.<\/p>\n\n\n\n

For employers on the hiring side, this geographic arbitrage is a sourcing strategy. A biosimilar manufacturer building commercial capacity in Cambridge, Massachusetts, or a biotech building a clinical team in San Diego, can access displaced talent from New Jersey restructurings at compensation levels that reflect the local market premium rather than the New Jersey pharmaceutical hub premium. The mismatch between where talent is released and where it is needed creates efficiency opportunities for organizations willing to recruit nationally.<\/p>\n\n\n\n

The Next Three Years: A Forward Calendar<\/strong><\/h2>\n\n\n\n

The patent cliff events of the next 36 months are knowable today. The organizational responses they will trigger are largely predictable based on the pattern established by the current cycle. What follows is a summary of the key workforce implications by year.<\/p>\n\n\n\n

2026: The Diabetes and Immunology Wave<\/strong><\/h3>\n\n\n\n

The Januvia and Janumet generic launches in May 2026 complete Merck’s diabetes commercial restructuring. Full Xeljanz generic entry eliminates the remaining rationale for Pfizer’s immunology sales force in that franchise. Trintellix’s December 2026 expiry drives Takeda’s neuroscience commercial reorganization that is already partially underway. Prevnar competitive dynamics affect Pfizer’s vaccine commercial organization.<\/p>\n\n\n\n

The hiring growth in 2026 concentrates at generics manufacturers building U.S. commercial infrastructure for sitagliptin and tofacitinib launches, at clinical development organizations supporting Merck’s and Pfizer’s successor pipeline assets, and at business development functions supporting the continued M&A wave.<\/p>\n\n\n\n

2027: Oncology and Breast Cancer Focus<\/strong><\/h3>\n\n\n\n

Ibrance’s March 2027 LOE in the United States drives Pfizer’s oncology commercial restructuring in the CDK4\/6 inhibitor space. Lynparza’s PARP inhibitor franchise begins its LOE transition for AstraZeneca and Merck. The biosimilar competitors for these oncology assets are already in development, and their commercial teams will need to be built before the LOE events arrive.<\/p>\n\n\n\n

The hiring growth in 2027 concentrates in oncology commercial specialists at biosimilar manufacturers, in clinical development for next-generation CDK inhibitors and PARP inhibitor combinations, and in market access functions supporting the complex hospital formulary navigation that oncology biosimilar launches require.<\/p>\n\n\n\n

2028 and Beyond: The Keytruda and Eliquis Inflection<\/strong><\/h3>\n\n\n\n

The 2028 LOE events for Keytruda and Eliquis will drive the most significant single-year restructuring events in the current cycle. Merck’s 6,000-position reduction is already underway in anticipation; BMS’s restructuring will continue through 2027 in preparation. By 2028, the hiring signal is at the biosimilar manufacturers and the next-generation oncology and cardiovascular companies who will compete in those spaces.<\/p>\n\n\n\n

Dupixent’s early 2030s LOE is the next major inflection point after 2028. Sanofi and Regeneron will face the same choices that BMS and Merck face today, and the organizational response will follow the same pattern. The professionals who understand how to read the signal in 2026 will be positioned to navigate that transition as well when it arrives.<\/p>\n\n\n\n

Key Takeaways<\/strong><\/h2>\n\n\n\n

Patent dates are organizational leading indicators.<\/strong> Companies begin restructuring 24 to 36 months before LOE events for small molecules, and 36 to 48 months before for biologics. By the time WARN filings appear, the decision is already 18 months old.<\/p>\n\n\n\n

The current cliff is three times the size of the previous one.<\/strong> The 2025-2030 window threatens $300 billion in pharmaceutical revenue \u2014 compared with $100 billion in the 2016 cycle. Seventeen large pharmaceutical companies collectively cut more than 22,000 positions in 2025 alone.<\/p>\n\n\n\n

The most exposed companies are identifiable today.<\/strong> BMS faces a $38 billion growth gap with 47% of revenues at risk by 2030. Merck’s Keytruda generates roughly $25 billion annually and faces LOE in 2028. These are not surprises; they are scheduled events with predictable organizational consequences.<\/p>\n\n\n\n

The workforce shift is bilateral.<\/strong> For every job eliminated at an originator company, hiring is growing at generics manufacturers, biosimilar developers, CROs, CDMOs, and the acquired pipeline assets that replacement M&A transactions bring into large pharma portfolios.<\/p>\n\n\n\n

Therapeutic area expertise transfers; product knowledge does not.<\/strong> Professionals who have built durable expertise in oncology, immunology, or cardiometabolic disease are far better positioned through patent cliff transitions than those whose expertise is specific to a single branded product.<\/p>\n\n\n\n

Tools like DrugPatentWatch operationalize the signal.<\/strong> Aggregating Orange Book data, Paragraph IV challenge filings, and LOE timelines into a usable analytical framework requires dedicated infrastructure. Using that infrastructure systematically \u2014 whether for investment research, recruiting, or career planning \u2014 is a competitive differentiator.<\/p>\n\n\n\n

The IRA runs alongside the patent cliff.<\/strong> Price negotiation under the Inflation Reduction Act affects drugs with remaining exclusivity and accelerates commercial pressure on drugs like Eliquis before their legal LOE date. Market access and HEOR professionals with IRA competency are in sustained demand regardless of how specific patent cliff events unfold.<\/p>\n\n\n\n

\n\n\n\n

FAQ<\/strong><\/h2>\n\n\n\n

Q1: How far in advance do pharmaceutical companies typically announce restructuring programs tied to patent cliff events, and why doesn’t the market already price this in?<\/p>\n\n\n\n

The announcement of restructuring programs tied to specific LOE events typically comes 18 to 36 months before the actual patent expiry. The reason markets do not fully price this in earlier is that pharmaceutical companies have historically delayed these announcements until revenue impact becomes visible in quarterly earnings, partly for workforce morale reasons and partly because activist investors can use restructuring announcements to pressure management. The market actually does price in patent cliff risk to some degree \u2014 BMS and Merck have traded at valuation discounts relative to less-exposed peers for years \u2014 but equity pricing tends to capture the revenue decline risk more than the specific organizational change implications. The workforce intelligence embedded in patent dates is an equity-uncorrelated signal that has more value for career professionals, consultants, and recruiters than for most investment strategies.<\/p>\n\n\n\n

Q2: Are sales representatives the only professionals with significant exposure, or are there other roles that face comparable restructuring risk?<\/p>\n\n\n\n

Sales representatives are the most visible and numerically largest affected population, but the restructuring wave runs deeper than commercial teams. Medical science liaisons, whose role is directly tied to the branded product’s clinical data and KOL relationships, face restructuring within 18 to 36 months of LOE. Market access teams supporting specific franchise reimbursement positions face rationalization once generic substitution begins and branded reimbursement negotiation becomes irrelevant. Regulatory affairs professionals working on lifecycle management for aging assets complete their work as the LOE approaches and find reduced organizational rationale afterward. Manufacturing and supply chain professionals face the longest lag, typically three to five years, but also face the largest absolute job count reductions as facilities close or convert to generic production. The safest functions through patent cliff events are those whose work is asset-agnostic: enterprise IT, corporate finance, human resources, and early-stage R&D not tied to specific commercial assets.<\/p>\n\n\n\n

Q3: Biosimilar entry is slower and less complete than generic entry. Does this mean the workforce implications for biologic LOE events are also slower and less severe?<\/p>\n\n\n\n

Slower, yes. Less severe in absolute terms, generally not. The revenue erosion from biosimilar competition is real \u2014 30% to 70% in the first year for most biologics \u2014 and it is permanent. The organizational infrastructure built to support a $9 billion Opdivo franchise cannot be maintained when Opdivo revenues drop to $3-4 billion. The timing difference is important for career planning: professionals working on biologic franchises facing LOE have more lead time than those on small-molecule drugs. But the direction of the organizational change is identical, and the endpoint is comparable. The slower erosion does give companies more time to execute strategic transitions, which is why the biosimilar restructuring announcements tend to come earlier relative to LOE than small-molecule restructuring announcements \u2014 companies use the longer runway to plan more carefully rather than simply delaying the inevitable.<\/p>\n\n\n\n

Q4: Which functional specialties are actually growing within large pharmaceutical companies despite the broader restructuring wave, and where should mid-career professionals be building expertise?<\/p>\n\n\n\n

Several functional areas are growing within large pharma even as total headcount contracts. Business development and alliance management professionals are in sustained demand as M&A activity accelerates. The $240 billion in pharma M&A deal value recorded in 2025 requires deal teams, due diligence specialists, and post-merger integration professionals who command premium compensation. Medical affairs professionals with expertise in next-generation modalities \u2014 antibody-drug conjugates, cell therapies, radiopharmaceuticals, protein degraders \u2014 are being hired to replace those working on legacy franchises. Regulatory affairs professionals with biologics license application (BLA) and biosimilar experience are valuable on both the originator and biosimilar manufacturer sides of every LOE event. Health economics and outcomes research specialists with IRA negotiation experience represent a relatively new specialty that is growing rapidly as the Medicare price negotiation process matures. Finally, data science and AI professionals with pharmaceutical domain expertise are being hired across R&D, manufacturing, and commercial functions as companies invest in digital transformation concurrent with workforce rationalization.<\/p>\n\n\n\n

Q5: Can a pharmaceutical company successfully use M&A to escape the patent cliff’s organizational consequences, or does acquisition activity simply shift the timing of workforce disruption?<\/p>\n\n\n\n

M&A is effective at replacing revenue on paper but rarely eliminates the organizational disruption associated with patent cliff events. When a company acquires a pipeline asset or an early-revenue product to fill a growth gap, that acquisition replaces projected revenue but brings a different organizational architecture. The commercial, medical affairs, and market access teams built around the expiring blockbuster are not the right teams to launch the new oncology or rare disease asset the acquisition brings. The skills, relationships, and call-point knowledge simply do not transfer. This is why Merck’s acquisition of Verona Pharma in respiratory does not save the jobs of the Januvia sales force, and why BMS’s investment in cell therapy and protein degraders does not preserve the Eliquis commercial team’s employment. What M&A does do is give the acquirer’s organization new functions to build \u2014 clinical development, regulatory affairs, and eventually commercial teams for the acquired asset \u2014 and those building functions partially offset the legacy workforce contraction. The net result is organizational transformation rather than net workforce growth, and the individuals who navigate it best are those who can credibly present themselves as candidates for the new functions being built rather than defenders of the old ones being eliminated.<\/p>\n\n\n\n

\n\n\n\n

References<\/strong><\/h2>\n\n\n\n
    \n
  1. Fierce Pharma. (2026, March 25). Large pharma companies reduced headcounts by more than 22K in 2025 as $300B patent cliff looms.<\/em> https:\/\/www.fiercepharma.com\/pharma\/large-pharma-companies-reduced-headcount-over-22000-2025-300b-patent-cliff-looms<\/li>\n\n\n\n
  2. Drug Discovery News. (2026, February 24). Blockbuster drugs face a massive patent cliff in 2026.<\/em> https:\/\/www.drugdiscoverynews.com\/blockbuster-drugs-face-a-massive-patent-cliff-in-2026-17019<\/li>\n\n\n\n
  3. GeneOnline News. (2025, March 7). Pharma faces $236 billion patent cliff by 2030: Key drugs and companies at risk.<\/em> https:\/\/www.geneonline.com\/pharma-faces-236-billion-patent-cliff-by-2030-key-drugs-and-companies-at-risk\/<\/li>\n\n\n\n
  4. IntuitionLabs. (2026). Drug patents expiring in 2026: A comprehensive guide.<\/em> https:\/\/intuitionlabs.ai\/articles\/drug-patent-expirations-2026<\/li>\n\n\n\n
  5. Global Pricing Innovations. (2025, November 4). Patent cliff in pharma: Navigating disruption and creating opportunity.<\/em> https:\/\/globalpricing.com\/patent-cliff-in-pharma-navigating-disruption-and-creating-opportunity\/<\/li>\n\n\n\n
  6. PharmaVoice. (2025, August 18). Biopharma layoffs rise as drugmakers tighten belts and reorganize.<\/em> https:\/\/www.pharmavoice.com\/news\/biopharma-layoffs-pharma-drug-moderna-bayer-merck\/757839\/<\/li>\n\n\n\n
  7. Chemistry World. (2024, June 17). Job cuts sweeping across pharmaceuticals.<\/em> https:\/\/www.chemistryworld.com\/news\/job-cuts-sweeping-across-pharmaceuticals\/4019655.article<\/li>\n\n\n\n
  8. PharmExec. (2026). Everything to know about pharma layoffs in 2025.<\/em> https:\/\/www.pharmexec.com\/view\/everything-know-layoffs-2025<\/li>\n\n\n\n
  9. PharmExec. (2026). Merck to cut 6,000 jobs as it aims for $3 billion in cost savings by 2027.<\/em> https:\/\/www.pharmexec.com\/view\/merck-cut-6-000-jobs-3-billion-cost-savings-2027<\/li>\n\n\n\n
  10. Xtalks. (2026). Pharma and biotech layoffs 2026 watch.<\/em> https:\/\/xtalks.com\/pharma-and-biotech-layoffs-2026-watch-4631\/<\/li>\n\n\n\n
  11. Fierce Pharma. (2026, March 30). Takeda begins US layoffs as part of massive $1.3B restructuring.<\/em> https:\/\/www.fiercepharma.com\/pharma\/takeda-begins-us-layoffs-part-massive-13b-restructuring<\/li>\n\n\n\n
  12. DeepCeutix. (2026, February 2). $300 billion in pharma revenue loses patent protection by 2030.<\/em> https:\/\/deepceutix.com\/insights\/patent-cliff-reformulation<\/li>\n\n\n\n
  13. DrugPatentWatch. (2026, March 12). The $236 billion cliff: How pharma loses its blockbusters \u2014 and what replaces them.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/as-blockbuster-drugs-fizzle-biotech-looks-warily-to-the-next-big-thing\/<\/li>\n\n\n\n
  14. DrugPatentWatch. (2026, February 2). The data-driven guide to winning the 2026 patent cliff.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/the-data-driven-guide-to-winning-the-2026-patent-cliff\/<\/li>\n\n\n\n
  15. Labiotech. (2026, March 23). The next pharma patent cliff: How 2026-2032 will reshape revenue.<\/em> https:\/\/www.labiotech.eu\/best-biotech\/pharma-patent-cliff\/<\/li>\n\n\n\n
  16. Foley & Lardner LLP. (2025, September). Will the next patent cliff further spur M&A activity and what does that mean for companies right now?<\/em> https:\/\/www.foley.com\/insights\/publications\/2025\/09\/patent-cliff-ma-activity-for-companies-right-now\/<\/li>\n\n\n\n
  17. Xtalks. (2026, January 12). Pharma and biotech layoffs 2025.<\/em> https:\/\/xtalks.com\/pharma-and-biotech-layoffs-2025-4110\/<\/li>\n\n\n\n
  18. Crisp Idea. (2025, July 29). Patent cliff 2025: Impact on pharma investors.<\/em> https:\/\/www.crispidea.com\/pharma-investing-patent-cliff-2025\/<\/li>\n\n\n\n
  19. IntuitionLabs. (2026, March 20). Pharma & CRO layoffs 2025-2026: An industry analysis.<\/em> https:\/\/intuitionlabs.ai\/articles\/pharma-cro-layoffs-2025-2026-analysis<\/li>\n\n\n\n
  20. PharmaVoice. (2025, March 10). What’s driving pharma’s layoffs in 2025.<\/em> https:\/\/www.pharmavoice.com\/news\/pharma-layoff-biotech-job-cut-biogen-bms-crispr\/741967\/<\/li>\n\n\n\n
  21. PMC \/ National Library of Medicine. (2016). Patent cliff and strategic switch: Exploring strategic design possibilities in the pharmaceutical industry.<\/em> https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC4899342\/<\/li>\n\n\n\n
  22. DrugPatentWatch. (2026, February 16). The drug patent cliff portfolio: A strategic guide to identifying and investing in companies facing major expiries.<\/em> https:\/\/www.drugpatentwatch.com\/blog\/the-drug-patent-cliff-portfolio-a-strategic-guide-to-identifying-and-investing-in-companies-facing-major-expiries\/<\/li>\n\n\n\n
  23. VIPS Law Blog. (2026, May 1). Navigating the surge in biopharma M&A.<\/em> https:\/\/vipslawblog.wordpress.com\/2026\/05\/01\/navigating-the-surge-in-biopharma-ma\/<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

    Before a pharmaceutical company files a single WARN notice, before a restructuring plan hits an SEC filing, before a CEO […]<\/p>\n","protected":false},"author":1,"featured_media":38683,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-38676","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38676","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=38676"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38676\/revisions"}],"predecessor-version":[{"id":38684,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/38676\/revisions\/38684"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/38683"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=38676"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=38676"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=38676"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}